AI · SaaS
Enterprise AI Market to Reach USD 273.08 Billion by 2031 as Cloud Adoption, Enterprise Automation, and AI-Led Decision Support Expand
Jul 24 · 18:40GetNews
As interest in gut-first weight management support grows in 2026, this Hello100 GLP-1 Booster review examines the brand-stated Akkermansia, artichoke-derived inulin, and B-vitamin formula, why its stimulant-free daily approach is attracting wellness-focused buyers, and the pricing, subscription, ingredient, and return-policy details to review before ordering.
As a participant in Anthropic's Cyber Verification Program, TrendAI applies frontier reasoning to convert vulnerability intelligence into faster protection across hybrid environments DALLAS, July 24, 2026 /PRNewswire/ -- TrendAI™, the enterprise AI security leader from Trend Micro...
Newly Designed Machines, Open-architecture CNC Control, Multiple Automation Systems, Intelligent Technologies, World-Class Services, Sustainable Initiatives, & More to be Featured CHARLOTTE, N.C., July 24, 2026 /PRNewswire/ -- The leadership team at Okuma America Corporation, a global...
Invitation-only professional community selects finance leader based on the depth and diversity of his experience EAGAN, Minn., July 24, 2026 /PRNewswire/ -- ImageTrend, the leading provider of software and AI intelligence for emergency response, healthcare and public safety organizations,...
BLUESKY DIGITAL ASSETS CORP. (the "Corporation")has scheduled a Special Meeting of common shareholders to be held on August 31, 2026The record date for determining shareholders of the Corporation entitled to receive notice of meeting is August 4, 2026. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/306435
New York, New York--(Newsfile Corp. - July 24, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Alignment Healthcare, Inc. ("Alignment Healthcare" or the "Company") (NASDAQ: ALHC).CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATIONIf you are an Alignment Healthcare investor and have suffered losses, or if you have information that could assist in the Alignment Healthcare investigation, you may CLICK HERE to contact us. You may also contact...
LOS ANGELES, CA - July 24, 2026 ( NEWMEDIAWIRE ) - VERAXA Biotech (NASDAQ: VRXA) announced the appointment of Christoph Erkel, Ph.D., as chief scientific officer, effective immediately. Erkel, previously vice president of research and development, will lead advancement of the company’s proprietary BiTAC(R) platform technologies for the development of cancer therapies targeting solid tumors. He succeeds Rick Austin, Ph.D., who will depart following a transition period. Erkel brings two decades of experience in antibody therapeutics, antibody engineering and preclinical development, including prior leadership roles at MorphoSys AG, where he led immuno-oncology programs focused on T-cell engagers. VERAXA said his experience managing multidisciplinary research programs will support efforts to
New product completes the brand's daily prevention system, backed by independent lab testing and South Korean DNA verification of super lice strains
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Shareholders should contact the...
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Shareholders should contact the...
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Shareholders should contact the...